Skip to main content
Erschienen in: Urologie in der Praxis 1/2019

16.01.2019 | Urologie | Extended Abstract

Erhöhtes PSA – wie weiter?

verfasst von: PD Dr. med. Marco Randazzo

Erschienen in: Urologie in der Praxis | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Auszug

Der PSA-Wert liegt aus epidemiologischer Sicht bei knapp 80 % der Männer < 2 ng/ml, was als normal zu werten ist. Jenen Männern mit einem Wert < 2 ng/ml kann Sicherheit gegeben werden, da das Vorliegen eines aggressiven Prostatakarzinoms als sehr unwahrscheinlich zu werten ist. Liegt der Wert wiederholt über 2 ng/ml, ist eine Berechnung des Risikos zu empfehlen. Wird eine Biopsie erwogen, ist vorgängig eine MRT der Prostata zur Biopsieplanung empfohlen. Die heutigen Biopsietechniken mittels Fusion von Ultraschall und MRT zeigen eine deutlich höhere Sensitivität für die Detektion von aggressiven Prostatakarzinomen. …
Literatur
1.
Zurück zum Zitat Wang MC et al (1979) Purification of a human prostate specific antigen. Invest Urol 17(2):159–163PubMed Wang MC et al (1979) Purification of a human prostate specific antigen. Invest Urol 17(2):159–163PubMed
2.
Zurück zum Zitat Graves HC, Sensabaugh GF, Blake ET (1985) Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 312(6):338–343CrossRef Graves HC, Sensabaugh GF, Blake ET (1985) Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 312(6):338–343CrossRef
3.
Zurück zum Zitat Stamey TA et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916CrossRef Stamey TA et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916CrossRef
4.
Zurück zum Zitat Catalona WJ et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17):1156–1161CrossRef Catalona WJ et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17):1156–1161CrossRef
5.
6.
Zurück zum Zitat Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68(2):603–616CrossRef Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68(2):603–616CrossRef
7.
Zurück zum Zitat Benson MC et al (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147(3 Pt 2):817–821CrossRef Benson MC et al (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147(3 Pt 2):817–821CrossRef
8.
Zurück zum Zitat Zlotta AR et al (1997) Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 157(4):1315–1321CrossRef Zlotta AR et al (1997) Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 157(4):1315–1321CrossRef
10.
Zurück zum Zitat Zlotta AR et al (2013) Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105(14):1050–1058CrossRef Zlotta AR et al (2013) Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105(14):1050–1058CrossRef
11.
Zurück zum Zitat Carter HB et al (2012) Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 30(35):4294–4296CrossRef Carter HB et al (2012) Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 30(35):4294–4296CrossRef
12.
Zurück zum Zitat Klotz L et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277CrossRef Klotz L et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277CrossRef
13.
Zurück zum Zitat Haffner MC et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922CrossRef Haffner MC et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922CrossRef
14.
Zurück zum Zitat Seiler D et al (2012) Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU Int 110(2):195–200CrossRef Seiler D et al (2012) Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU Int 110(2):195–200CrossRef
15.
Zurück zum Zitat Crawford ED et al (1992) The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267(16):2227–2228CrossRef Crawford ED et al (1992) The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267(16):2227–2228CrossRef
16.
Zurück zum Zitat Borgermann C et al (2011) PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! Cancer Epidemiol Biomarkers Prev 20(6):1190–1195CrossRef Borgermann C et al (2011) PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! Cancer Epidemiol Biomarkers Prev 20(6):1190–1195CrossRef
19.
Zurück zum Zitat Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343–346CrossRef Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343–346CrossRef
20.
Zurück zum Zitat Randazzo M et al (2015) Is further screening of men with baseline PSA 〈 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). Int J Cancer 137(3):553–559CrossRef Randazzo M et al (2015) Is further screening of men with baseline PSA 〈 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). Int J Cancer 137(3):553–559CrossRef
21.
Zurück zum Zitat Carter HB et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215–2220CrossRef Carter HB et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215–2220CrossRef
22.
Zurück zum Zitat Vickers AJ et al (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27(3):398–403CrossRef Vickers AJ et al (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27(3):398–403CrossRef
24.
Zurück zum Zitat Mortezavi A et al (2018) Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol 200(2):309–318CrossRef Mortezavi A et al (2018) Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol 200(2):309–318CrossRef
Metadaten
Titel
Erhöhtes PSA – wie weiter?
verfasst von
PD Dr. med. Marco Randazzo
Publikationsdatum
16.01.2019
Verlag
Springer Vienna
Schlagwort
Urologie
Erschienen in
Urologie in der Praxis / Ausgabe 1/2019
Print ISSN: 2661-8737
Elektronische ISSN: 2661-8745
DOI
https://doi.org/10.1007/s41973-019-0042-2

Weitere Artikel der Ausgabe 1/2019

Urologie in der Praxis 1/2019 Zur Ausgabe

Editorial

Editorial